Metraipolis › archive › dc_06ce27dbf99d
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial — Europe PMC PMID:42350643
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42350643
- DOI
- 10.1038/s41591-[numero omesso]-z
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-31T08:50:58.467Z
- SHA-256 of the archived text
85bd4501b3155d8eb5b11d598a70e9894c906356f059faecfcd085a578d85cb5- Stable URL of this page
https://metraipolis.com/documento/dc_06ce27dbf99d
How to cite
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial — Europe PMC PMID:42350643 — Europe PMC (en), https://europepmc.org/article/MED/42350643 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_06ce27dbf99d (Metraipolis archive dc_06ce27dbf99d, sha256 85bd4501b3155d8eb5b11d598a70e9894c906356f059faecfcd085a578d85cb5)
BibTeX
@misc{dc06ce27dbf99d,
title = {Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial — Europe PMC PMID:42350643},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42350643},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_06ce27dbf99d; sha256 85bd4501b3155d8eb5b11d598a70e9894c906356f059faecfcd085a578d85cb5},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42350643. Agents can read the archived copy with the MCP tool read_document.